Description
AMP-224 is an experimental drug being studied by the National Cancer Institute (NCI) for metastatic colorectal cancer. It is being tested in combination with stereotactic body radiation therapy (SBRT) in patients whose cancer has progressed after treatment with oxaliplatin and irinotecan. The trial aims to see if this combination is safe and feasible. AMP-224 is a type of immunotherapy that targets the PD-1 protein on certain types of immune cells (T cells). The study also includes a single dose of cyclophosphamide, another medication, given with the radiation therapy. Patients in the trial must have a liver lesion suitable for SBRT and at least one other measurable lesion outside the radiation field. The trial requires pre- and post-treatment tumor biopsies.
Mechanism of Action
AMP-224 is a B7-DC Fc fusion protein. It works by binding to the PD-1 protein, which is found on the surface of certain immune cells called T cells. Specifically, it targets PD-1HI T cells, which are chronically stimulated or exhausted T cells. By binding to PD-1, AMP-224 aims to block the signals that normally suppress the activity of these T cells, potentially enhancing the body's immune response against the cancer. The trial is investigating whether combining AMP-224 with radiation therapy can further boost this anti-tumor immunity.
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.